| { |
| "architectures": [ |
| "BertForSequenceClassification" |
| ], |
| "attention_probs_dropout_prob": 0.1, |
| "bos_token_id": 0, |
| "classifier_dropout": null, |
| "dtype": "float32", |
| "eos_token_ids": 0, |
| "hidden_act": "gelu", |
| "hidden_dropout_prob": 0.1, |
| "hidden_size": 1024, |
| "id2label": { |
| "0": "1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING", |
| "1": "1.2 PSYCHOLOGICAL AND SOCIOECONOMIC PROCESSES", |
| "2": "1.3 CHEMICAL AND PHYSICAL SCIENCES", |
| "3": "1.4 METHODOLOGIES AND MEASUREMENTS", |
| "4": "1.5 RESOURCES AND INFRASTRUCTURE (UNDERPINNING)", |
| "5": "2.1 BIOLOGICAL AND ENDOGENOUS FACTORS", |
| "6": "2.2 FACTORS RELATING TO PHYSICAL ENVIRONMENT", |
| "7": "2.3 PSYCHOLOGICAL, SOCIAL AND ECONOMIC FACTORS", |
| "8": "2.4 SURVEILLANCE AND DISTRIBUTION", |
| "9": "2.5 RESEARCH DESIGN AND METHODOLOGIES (AETIOLOGY)", |
| "10": "2.6 RESOURCES AND INFRASTRUCTURE (AETIOLOGY)", |
| "11": "3.1 PRIMARY PREVENTION INTERVENTIONS TO MODIFY BEHAVIOURS OR PROMOTE WELL-BEING", |
| "12": "3.2 INTERVENTIONS TO ALTER PHYSICAL AND BIOLOGICAL ENVIRONMENTAL RISKS", |
| "13": "3.3 NUTRITION AND CHEMOPREVENTION", |
| "14": "3.4 VACCINES", |
| "15": "3.5 RESOURCES AND INFRASTRUCTURE (PREVENTION)", |
| "16": "4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES", |
| "17": "4.2 EVALUATION OF MARKERS AND TECHNOLOGIES", |
| "18": "4.3 INFLUENCES AND IMPACT", |
| "19": "4.4 POPULATION SCREENING", |
| "20": "4.5 RESOURCES AND INFRASTRUCTURE (DETECTION)", |
| "21": "5.1 PHARMACEUTICALS", |
| "22": "5.2 CELLULAR AND GENE THERAPIES", |
| "23": "5.3 MEDICAL DEVICES", |
| "24": "5.4 SURGERY", |
| "25": "5.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES", |
| "26": "5.6 PSYCHOLOGICAL AND BEHAVIOURAL", |
| "27": "5.7 PHYSICAL", |
| "28": "5.8 COMPLEMENTARY", |
| "29": "5.9 RESOURCES AND INFRASTRUCTURE (TREATMENT DEVELOPMENT)", |
| "30": "6.1 PHARMACEUTICALS", |
| "31": "6.2 CELLULAR AND GENE THERAPIES", |
| "32": "6.3 MEDICAL DEVICES", |
| "33": "6.4 SURGERY", |
| "34": "6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES", |
| "35": "6.6 PSYCHOLOGICAL AND BEHAVIOURAL", |
| "36": "6.7 PHYSICAL", |
| "37": "6.8 COMPLEMENTARY", |
| "38": "6.9 RESOURCES AND INFRASTRUCTURE (TREATMENT EVALUATION)", |
| "39": "7.1 INDIVIDUAL CARE NEEDS", |
| "40": "7.2 END OF LIFE CARE", |
| "41": "7.3 MANAGEMENT AND DECISION MAKING", |
| "42": "7.4 RESOURCES AND INFRASTRUCTURE (DISEASE MANAGEMENT)", |
| "43": "8.1 ORGANISATION AND DELIVERY OF SERVICES", |
| "44": "8.2 HEALTH AND WELFARE ECONOMICS", |
| "45": "8.3 POLICY, ETHICS AND RESEARCH GOVERNANCE", |
| "46": "8.4 RESEARCH DESIGN AND METHODOLOGIES (HEALTH SERVICES)", |
| "47": "8.5 RESOURCES AND INFRASTRUCTURE (HEALTH SERVICES)" |
| }, |
| "initializer_range": 0.02, |
| "intermediate_size": 4096, |
| "label2id": { |
| "1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING": 0, |
| "1.2 PSYCHOLOGICAL AND SOCIOECONOMIC PROCESSES": 1, |
| "1.3 CHEMICAL AND PHYSICAL SCIENCES": 2, |
| "1.4 METHODOLOGIES AND MEASUREMENTS": 3, |
| "1.5 RESOURCES AND INFRASTRUCTURE (UNDERPINNING)": 4, |
| "2.1 BIOLOGICAL AND ENDOGENOUS FACTORS": 5, |
| "2.2 FACTORS RELATING TO PHYSICAL ENVIRONMENT": 6, |
| "2.3 PSYCHOLOGICAL, SOCIAL AND ECONOMIC FACTORS": 7, |
| "2.4 SURVEILLANCE AND DISTRIBUTION": 8, |
| "2.5 RESEARCH DESIGN AND METHODOLOGIES (AETIOLOGY)": 9, |
| "2.6 RESOURCES AND INFRASTRUCTURE (AETIOLOGY)": 10, |
| "3.1 PRIMARY PREVENTION INTERVENTIONS TO MODIFY BEHAVIOURS OR PROMOTE WELL-BEING": 11, |
| "3.2 INTERVENTIONS TO ALTER PHYSICAL AND BIOLOGICAL ENVIRONMENTAL RISKS": 12, |
| "3.3 NUTRITION AND CHEMOPREVENTION": 13, |
| "3.4 VACCINES": 14, |
| "3.5 RESOURCES AND INFRASTRUCTURE (PREVENTION)": 15, |
| "4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES": 16, |
| "4.2 EVALUATION OF MARKERS AND TECHNOLOGIES": 17, |
| "4.3 INFLUENCES AND IMPACT": 18, |
| "4.4 POPULATION SCREENING": 19, |
| "4.5 RESOURCES AND INFRASTRUCTURE (DETECTION)": 20, |
| "5.1 PHARMACEUTICALS": 21, |
| "5.2 CELLULAR AND GENE THERAPIES": 22, |
| "5.3 MEDICAL DEVICES": 23, |
| "5.4 SURGERY": 24, |
| "5.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES": 25, |
| "5.6 PSYCHOLOGICAL AND BEHAVIOURAL": 26, |
| "5.7 PHYSICAL": 27, |
| "5.8 COMPLEMENTARY": 28, |
| "5.9 RESOURCES AND INFRASTRUCTURE (TREATMENT DEVELOPMENT)": 29, |
| "6.1 PHARMACEUTICALS": 30, |
| "6.2 CELLULAR AND GENE THERAPIES": 31, |
| "6.3 MEDICAL DEVICES": 32, |
| "6.4 SURGERY": 33, |
| "6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES": 34, |
| "6.6 PSYCHOLOGICAL AND BEHAVIOURAL": 35, |
| "6.7 PHYSICAL": 36, |
| "6.8 COMPLEMENTARY": 37, |
| "6.9 RESOURCES AND INFRASTRUCTURE (TREATMENT EVALUATION)": 38, |
| "7.1 INDIVIDUAL CARE NEEDS": 39, |
| "7.2 END OF LIFE CARE": 40, |
| "7.3 MANAGEMENT AND DECISION MAKING": 41, |
| "7.4 RESOURCES AND INFRASTRUCTURE (DISEASE MANAGEMENT)": 42, |
| "8.1 ORGANISATION AND DELIVERY OF SERVICES": 43, |
| "8.2 HEALTH AND WELFARE ECONOMICS": 44, |
| "8.3 POLICY, ETHICS AND RESEARCH GOVERNANCE": 45, |
| "8.4 RESEARCH DESIGN AND METHODOLOGIES (HEALTH SERVICES)": 46, |
| "8.5 RESOURCES AND INFRASTRUCTURE (HEALTH SERVICES)": 47 |
| }, |
| "layer_norm_eps": 1e-12, |
| "max_position_embeddings": 512, |
| "model_type": "bert", |
| "num_attention_heads": 16, |
| "num_hidden_layers": 24, |
| "output_past": true, |
| "pad_token_id": 0, |
| "position_embedding_type": "absolute", |
| "problem_type": "multi_label_classification", |
| "transformers_version": "4.57.0", |
| "type_vocab_size": 2, |
| "use_cache": true, |
| "vocab_size": 30522 |
| } |
|
|
